Mylan N.V. (NASDAQ:MYL) has climbed 1.08% in the past week and advanced 8.43% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 2.29% and the outperformance has advanced to 7.44% for the last 4 weeks period.
Mylan N.V. (NASDAQ:MYL): The stock opened at $45.05 on Friday but the bulls could not build on the opening and the stock topped out at $45.58 for the day. The stock traded down to $44.47 during the day, due to lack of any buying support eventually closed down at $45.01 with a loss of -0.09% for the day. The stock had closed at $45.05 on the previous day. The total traded volume was 9,207,438 shares.
The company shares have dropped -37.15% from its 1 Year high price. On Jul 6, 2015, the shares registered one year high at $73.90 and the one year low was seen on Oct 22, 2015. The 50-Day Moving Average price is $42.85 and the 200 Day Moving Average price is recorded at $47.49.
On the companys insider trading activities, Maroon Joseph C Md, director of Mylan N.V., executed a transaction worth $75,067 on June 3, 2016. A total of 1,670 shares were purchased at an average price of $44.95. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Many analysts have stated their opinion on the company shares. In the latest statement by the brokerage house, Leerink Swann maintains its outlook on Mylan N.V. (NASDAQ:MYL). The current rating of the shares is Outperform, according to the research report released by the firm. The brokerage firm lowers the price target from $53 per share to $51 per share. The rating by the firm was issued on May 4, 2016. Currently the company Insiders own 0.71% of Mylan N.V. shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -13.09% . Institutional Investors own 66.47% of Mylan N.V. shares. During last six month period, the net percent change held by insiders has seen a change of -11.04%.
Mylan N.V., formerly Mylan Inc., is a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan operates in two segments: Generics and Specialty. The Companys generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its specialty pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). The Companys API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. Mylan provides products to customers in approximately 140 countries and territories.